Avalo Therapeutics, Inc. (AVTX) fundamentals score
Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Its lead product candidate, abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody (“mAb”) is in a Phase 2 clinical trial for hidradenitis suppurativa (“HS”).
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 3.0 out of 10, Unhealthy fundamentals
- Growth: 1.3/10
- Profitability: 1.0/10
- Financial health: 7.5/10
- Earnings quality: 4.4/10
- Valuation: 1.5/10
Scores are calculated from Avalo Therapeutics, Inc.’s SEC filings, using the 12 months through 2024-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10